{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T21:45:07Z","timestamp":1785879907737,"version":"3.56.0"},"reference-count":60,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,7]],"date-time":"2026-06-07T00:00:00Z","timestamp":1780790400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100024201","name":"Fundaci\u00f3n P\u00fablica Andaluza para la Investigaci\u00f3n de M\u00e1laga en Biomedicina y Salud","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100024201","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thebreastonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Breast"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.breast.2026.104833","type":"journal-article","created":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T18:02:44Z","timestamp":1781200964000},"page":"104833","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Association between antibiotic use and pathologic response to neoadjuvant chemotherapy in breast cancer: a multicentre retrospective cohort study"],"prefix":"10.1016","volume":"88","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8343-1815","authenticated-orcid":false,"given":"M.","family":"Zalabardo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Girona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1.","family":"Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Blanco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00d3.","family":"Campos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"S\u00e1nchez-Mu\u00f1oz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.L.","family":"Onieva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.M.","family":"Jerez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Pascual","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.J.","family":"Bermejo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Jim\u00e9nez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"M\u00e1rquez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.I.","family":"Pajares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Dom\u00ednguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Godoy-Ortiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"D\u00edaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Zarcos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Carabantes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Villar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Ribelles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Alba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.breast.2026.104833_bib1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"issue":"6","key":"10.1016\/j.breast.2026.104833_bib2","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1634\/theoncologist.9-6-606","article-title":"Prognostic and predictive factors in early-stage breast cancer","volume":"9","author":"Cianfrocca","year":"2004","journal-title":"Oncologist"},{"issue":"5","key":"10.1016\/j.breast.2026.104833_bib3","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1053\/j.semdp.2022.06.015","article-title":"Update on prognostic and predictive biomarkers of breast cancer","volume":"39","author":"Hou","year":"2022","journal-title":"Semin Diagn Pathol"},{"issue":"1","key":"10.1016\/j.breast.2026.104833_bib4","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s10549-010-1113-7","article-title":"Defining breast cancer prognosis based on molecular phenotypes: results from a large cohort study","volume":"126","author":"Dawood","year":"2011","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.breast.2026.104833_bib5","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1200\/EDBK_237715","article-title":"Molecular testing in breast cancer","volume":"39","author":"Litton","year":"2019","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"3","key":"10.1016\/j.breast.2026.104833_bib6","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1093\/jnci\/dji021","article-title":"Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis","volume":"97","author":"Mauri","year":"2005","journal-title":"J Natl Cancer Inst"},{"issue":"26","key":"10.1016\/j.breast.2026.104833_bib7","doi-asserted-by":"crossref","first-page":"2438","DOI":"10.1056\/NEJMp1205737","article-title":"Pathological complete response and accelerated drug approval in early breast cancer","volume":"366","author":"Prowell","year":"2012","journal-title":"N Engl J Med"},{"issue":"43","key":"10.1016\/j.breast.2026.104833_bib8","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1093\/jncimonographs\/lgr028","article-title":"Neoadjuvant chemotherapy: early response as a guide for further treatment: clinical, radiological, and biological","author":"Untch","year":"2011","journal-title":"J Natl Cancer Inst Monogr"},{"issue":"9938","key":"10.1016\/j.breast.2026.104833_bib9","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S0140-6736(13)62422-8","article-title":"Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis","volume":"384","author":"Cortazar","year":"2014","journal-title":"Lancet"},{"issue":"15","key":"10.1016\/j.breast.2026.104833_bib10","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1200\/JCO.2011.38.8595","article-title":"Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes","volume":"30","author":"von Minckwitz","year":"2012","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.breast.2026.104833_bib11","doi-asserted-by":"crossref","first-page":"2838","DOI":"10.1158\/1078-0432.CCR-19-3492","article-title":"Pathologic complete response after neoadjuvant chemotherapy and impact on recurrence and survival: a comprehensive meta-analysis","volume":"26","author":"Spring","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.breast.2026.104833_bib12","series-title":"Effectiveness of cancer treatments threatened by rising antibiotic resistance","year":"2020"},{"key":"10.1016\/j.breast.2026.104833_bib13","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s41523-024-00630-w","article-title":"Association of antibiotic exposure with residual cancer burden in HER2-negative early-stage breast cancer","volume":"10","author":"Kulkarni","year":"2024","journal-title":"npj Breast Cancer"},{"key":"10.1016\/j.breast.2026.104833_bib14","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/ni.3754","article-title":"Nutrition, inflammation and cancer","volume":"18","author":"Zitvogel","year":"2017","journal-title":"Nat Immunol"},{"issue":"1","key":"10.1016\/j.breast.2026.104833_bib15","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/s41392-023-01406-7","article-title":"Role of the gut microbiota in anticancer therapy: from molecular mechanisms to clinical applications","volume":"8","author":"Zhao","year":"2023","journal-title":"Signal Transduct Targeted Ther"},{"issue":"6230","key":"10.1016\/j.breast.2026.104833_bib16","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1126\/science.aaa4972","article-title":"Cancer and the microbiota","volume":"348","author":"Garrett","year":"2015","journal-title":"Science"},{"issue":"6","key":"10.1016\/j.breast.2026.104833_bib17","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1016\/j.cell.2012.01.035","article-title":"The impact of the gut microbiota on human health: an integrative view","volume":"148","author":"Clemente","year":"2012","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.breast.2026.104833_bib18","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/s41392-022-00974-4","article-title":"Microbiota in health and diseases","volume":"7","author":"Hou","year":"2022","journal-title":"Signal Transduct Targeted Ther"},{"issue":"7415","key":"10.1016\/j.breast.2026.104833_bib19","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1038\/nature11552","article-title":"Functional interactions between the gut microbiota and host metabolism","volume":"489","author":"Tremaroli","year":"2012","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.breast.2026.104833_bib20","doi-asserted-by":"crossref","first-page":"2778","DOI":"10.1038\/s41418-021-00784-1","article-title":"Intestinal microbiota influences clinical outcome and side effects of early breast cancer treatment","volume":"28","author":"Terrisse","year":"2021","journal-title":"Cell Death Differ"},{"issue":"6264","key":"10.1016\/j.breast.2026.104833_bib21","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1126\/science.aac4255","article-title":"Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy","volume":"350","author":"Sivan","year":"2015","journal-title":"Science"},{"issue":"11","key":"10.1016\/j.breast.2026.104833_bib22","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1038\/s41575-019-0209-8","article-title":"Gut microbiota in colorectal cancer: mechanisms of action and clinical applications","volume":"16","author":"Wong","year":"2019","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"12","key":"10.1016\/j.breast.2026.104833_bib23","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1001\/jamaoncol.2019.2785","article-title":"Association of prior antibiotic treatment with survival and response to immune checkpoint inhibitor therapy in patients with cancer","volume":"5","author":"Pinato","year":"2019","journal-title":"JAMA Oncol"},{"issue":"2","key":"10.1016\/j.breast.2026.104833_bib24","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1093\/jnci\/djaa057","article-title":"Association of antibiotic exposure with survival and toxicity in patients with melanoma receiving immunotherapy","volume":"113","author":"Mohiuddin","year":"2021","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"10.1016\/j.breast.2026.104833_bib25","article-title":"Antibiotics modulate neoadjuvant therapy efficiency in patients with breast cancer: a pilot analysis","volume":"11","author":"Zhang","year":"2021","journal-title":"Sci Rep"},{"issue":"6","key":"10.1016\/j.breast.2026.104833_bib26","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/nrgastro.2017.20","article-title":"Gut microbiota modulation of chemotherapy efficacy and toxicity","volume":"14","author":"Alexander","year":"2017","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"28","key":"10.1016\/j.breast.2026.104833_bib27","doi-asserted-by":"crossref","first-page":"4414","DOI":"10.1200\/JCO.2007.10.6823","article-title":"Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy","volume":"25","author":"Symmans","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2026.104833_bib28","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.jclinepi.2022.04.003","article-title":"Antibiotic exposure within six months before systemic therapy was associated with lower cancer survival","volume":"147","author":"Morrell","year":"2022","journal-title":"J Clin Epidemiol"},{"issue":"6","key":"10.1016\/j.breast.2026.104833_bib29","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1093\/annonc\/mdy103","article-title":"Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer","volume":"29","author":"Derosa","year":"2018","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.breast.2026.104833_bib30","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/s41698-024-00630-w","article-title":"Antibiotics are associated with worse outcomes in lung cancer patients treated with chemotherapy and immunotherapy","volume":"8","author":"Elkrief","year":"2024","journal-title":"npj Precis Oncol"},{"issue":"6","key":"10.1016\/j.breast.2026.104833_bib31","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.ijmedinf.2012.08.001","article-title":"Addressing critical issues in the development of an Oncology information system","volume":"82","author":"Urda","year":"2013","journal-title":"Int J Med Inf"},{"issue":"4","key":"10.1016\/j.breast.2026.104833_bib32","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.jclinepi.2007.11.008","article-title":"The strengthening the reporting of observational studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"61","author":"von","year":"2008","journal-title":"J Clin Epidemiol"},{"issue":"10","key":"10.1016\/j.breast.2026.104833_bib33","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1200\/JCO.2015.63.1010","article-title":"Long-term prognostic risk after neoadjuvant chemotherapy associated with residual cancer burden and breast cancer subtype","volume":"35","author":"Symmans","year":"2017","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.breast.2026.104833_bib34","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S1470-2045(21)00589-1","article-title":"Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients","volume":"23","author":"Yau","year":"2022","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.breast.2026.104833_bib35","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0234191","article-title":"Prognostic value of the residual cancer burden index according to breast cancer subtype: validation on a cohort of BC patients treated by neoadjuvant chemotherapy","volume":"15","author":"Hamy","year":"2020","journal-title":"PLoS One"},{"issue":"9","key":"10.1016\/j.breast.2026.104833_bib36","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1093\/annonc\/mdt303","article-title":"Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International expert Consensus on the Primary therapy of Early Breast Cancer 2013","volume":"24","author":"Goldhirsch","year":"2013","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.breast.2026.104833_bib37","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s10549-011-1949-5","article-title":"Incidence of reduced chemotherapy relative dose intensity among women with early stage breast cancer in US clinical practice","volume":"133","author":"Weycker","year":"2012","journal-title":"Breast Cancer Res Treat"},{"issue":"14","key":"10.1016\/j.breast.2026.104833_bib38","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1056\/NEJM199504063321401","article-title":"Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up","volume":"332","author":"Bonadonna","year":"1995","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.breast.2026.104833_bib39","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s10549-015-3418-z","article-title":"Relative dose intensity and therapy efficacy in different breast cancer molecular subtypes: a retrospective study of early stage breast cancer patients treated with neoadjuvant chemotherapy","volume":"151","author":"Yuan","year":"2015","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"10.1016\/j.breast.2026.104833_bib40","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-70187-8","article-title":"The effect of reduced RDI of chemotherapy on the outcome of breast cancer patients","volume":"10","author":"Qi","year":"2020","journal-title":"Sci Rep"},{"issue":"2","key":"10.1016\/j.breast.2026.104833_bib41","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1200\/JCO.22.01440","article-title":"Low-intensity adjuvant chemotherapy for breast cancer in older women: results from the prospective multicenter HOPE trial","volume":"41","author":"Sedrak","year":"2023","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.breast.2026.104833_bib42","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1038\/s41467-023-37636-0","article-title":"Antimicrobial exposure is associated with decreased survival in triple-negative breast cancer","volume":"14","author":"Ransohoff","year":"2023","journal-title":"Nat Commun"},{"issue":"8","key":"10.1016\/j.breast.2026.104833_bib43","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1158\/0008-5472.CAN-20-1659","article-title":"Gut microbiota condition the therapeutic efficacy of trastuzumab in HER2-positive breast cancer","volume":"81","author":"Di Modica","year":"2021","journal-title":"Cancer Res"},{"key":"10.1016\/j.breast.2026.104833_bib44","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/7849108","article-title":"Predicting the efficacy of HER2-targeted therapies: a look at the host","volume":"2017","author":"Di Modica","year":"2017","journal-title":"Dis Markers"},{"key":"10.1016\/j.breast.2026.104833_bib45","first-page":"209","article-title":"Conventional chemotherapy: millions of cures, unresolved therapeutic index","volume":"25","author":"Letai","year":"2025","journal-title":"Nat Rev Cancer"},{"issue":"10","key":"10.1016\/j.breast.2026.104833_bib46","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/j.ccell.2021.08.006","article-title":"Microbiome and cancer","volume":"39","author":"Cullin","year":"2021","journal-title":"Cancer Cell"},{"issue":"11","key":"10.1016\/j.breast.2026.104833_bib47","article-title":"Gastrointestinal Microbiota and breast cancer chemotherapy interactions: a systematic review","volume":"14","author":"Csendes","year":"2022","journal-title":"Cureus"},{"key":"10.1016\/j.breast.2026.104833_bib48","article-title":"Metagenomic analyses reveal distinct gut Microbiota signature for predicting the neoadjuvant chemotherapy responsiveness in breast cancer patients","volume":"12","author":"Li","year":"2022","journal-title":"Front Oncol"},{"issue":"3","key":"10.1016\/j.breast.2026.104833_bib49","doi-asserted-by":"crossref","first-page":"223","DOI":"10.2165\/00003088-198611030-00004","article-title":"Pharmacokinetic drug interactions of commonly used anticancer drugs","volume":"11","author":"Balis","year":"1986","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"10.1016\/j.breast.2026.104833_bib50","doi-asserted-by":"crossref","first-page":"299","DOI":"10.37201\/req\/037.2024","article-title":"Clinically important pharmacokinetic drug-drug interactions with antibacterial agents","volume":"37","author":"Torrent Rodr\u00edguez","year":"2024","journal-title":"Rev Espa\u00f1ola Quimioter"},{"issue":"1","key":"10.1016\/j.breast.2026.104833_bib51","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1186\/s12885-020-06855-9","article-title":"Prevalence and significance of potential drug-drug interactions among cancer patients receiving chemotherapy","volume":"20","author":"Ismail","year":"2020","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.breast.2026.104833_bib52","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.cell.2014.03.011","article-title":"Role of the microbiota in immunity and inflammation","volume":"157","author":"Belkaid","year":"2014","journal-title":"Cell"},{"issue":"11","key":"10.1016\/j.breast.2026.104833_bib53","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1038\/s41419-020-03221-2","article-title":"Detection of immunogenic cell death and its relevance for cancer therapy","volume":"11","author":"Fucikova","year":"2020","journal-title":"Cell Death Dis"},{"issue":"1","key":"10.1016\/j.breast.2026.104833_bib54","doi-asserted-by":"crossref","first-page":"40","DOI":"10.32607\/actanaturae.11523","article-title":"Immunogenic cell death in cancer therapy","volume":"14","author":"Troitskaya","year":"2022","journal-title":"Acta Nat"},{"issue":"14","key":"10.1016\/j.breast.2026.104833_bib55","doi-asserted-by":"crossref","first-page":"4809","DOI":"10.1158\/0008-5472.CAN-11-0753","article-title":"Pivotal role of innate and adaptive immunity in anthracycline chemotherapy of established tumors","volume":"71","author":"Mattarollo","year":"2011","journal-title":"Cancer Res"},{"key":"10.1016\/j.breast.2026.104833_bib56","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1038\/s41590-025-02289-2","article-title":"Chemotherapy-induced CA-repeat DNA fragments in breast cancer trigger antitumor immune responses","volume":"26","author":"Zhang","year":"2025","journal-title":"Nat Immunol"},{"issue":"6","key":"10.1016\/j.breast.2026.104833_bib57","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1038\/s41591-019-0432-4","article-title":"Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial","volume":"25","author":"Voorwerk","year":"2019","journal-title":"Nat Med"},{"issue":"6536","key":"10.1016\/j.breast.2026.104833_bib58","doi-asserted-by":"crossref","first-page":"eabc4552","DOI":"10.1126\/science.abc4552","article-title":"The microbiome and human cancer","volume":"371","author":"Sepich-Poore","year":"2021","journal-title":"Science"},{"issue":"6161","key":"10.1016\/j.breast.2026.104833_bib59","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1126\/science.1240537","article-title":"The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide","volume":"342","author":"Viaud","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.breast.2026.104833_bib60","article-title":"Evaluation of pathological complete response as surrogate endpoint in neoadjuvant randomised clinical trials of early-stage breast cancer: systematic review and meta-analysis","volume":"375","author":"Conforti","year":"2021","journal-title":"BMJ"}],"container-title":["The Breast"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977626001438?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977626001438?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T20:54:48Z","timestamp":1785876888000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960977626001438"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":60,"alternative-id":["S0960977626001438"],"URL":"https:\/\/doi.org\/10.1016\/j.breast.2026.104833","relation":{},"ISSN":["0960-9776"],"issn-type":[{"value":"0960-9776","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Association between antibiotic use and pathologic response to neoadjuvant chemotherapy in breast cancer: a multicentre retrospective cohort study","name":"articletitle","label":"Article Title"},{"value":"The Breast","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.breast.2026.104833","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"104833"}}